Anticoagulants: Warfarin to DOACs
Anticoagulants prevent thrombus formation by targeting different points in the coagulation cascade. The shift from warfarin to direct oral anticoagulants has simplified management for many patients.
Coagulation Cascade Overview
The coagulation cascade converges on thrombin (Factor IIa), which converts fibrinogen to fibrin, forming the structural basis of a clot. Anticoagulants target different points: vitamin K-dependent factor synthesis (warfarin), thrombin directly (dabigatran), or Factor Xa (rivaroxaban, apixaban, edoxaban).
Warfarin
Warfarin inhibits vitamin K epoxide reductase (VKORC1), preventing regeneration of the reduced form of vitamin K needed for gamma-carboxylation of clotting factors II, VII, IX, and X. Because it blocks synthesis of new factors rather than inactivating existing ones, full anticoagulant effect takes 5-7 days.
Monitoring: International Normalized Ratio (INR), target typically 2.0-3.0 for atrial fibrillation and VTE (2.5-3.5 for mechanical heart valves).
Challenges: Narrow therapeutic index, extensive drug and food interactions (CYP2C9, CYP3A4, vitamin K-rich foods), genetic polymorphisms in VKORC1 and CYP2C9 causing variable dosing requirements. Requires frequent blood tests.
Reversal: Vitamin K (phytonadione) for non-emergent reversal. Four-factor prothrombin complex concentrate (4F-PCC) or fresh frozen plasma for urgent bleeding.
Direct Oral Anticoagulants (DOACs)
| DOAC | Target | Half-Life | Renal Clearance | Reversal Agent |
|---|---|---|---|---|
| Dabigatran | Thrombin (IIa) | 12-17 h | 80% | Idarucizumab |
| Rivaroxaban | Factor Xa | 5-9 h | 33% | Andexanet alfa |
| Apixaban | Factor Xa | 12 h | 27% | Andexanet alfa |
| Edoxaban | Factor Xa | 10-14 h | 50% | Andexanet alfa |
DOACs offer predictable pharmacokinetics, fixed dosing, no routine monitoring, rapid onset (2-4 hours), fewer food interactions, and lower intracranial hemorrhage risk compared to warfarin.
Clinical Indications
- Non-valvular atrial fibrillation -- DOACs are preferred over warfarin for stroke prevention (DOAC trials: RE-LY, ROCKET-AF, ARISTOTLE, ENGAGE AF).
- Venous thromboembolism -- Treatment and extended prophylaxis of DVT and PE. Apixaban and rivaroxaban allow single-drug approaches without initial heparin bridging.
- Mechanical heart valves -- Warfarin remains the ONLY option. Dabigatran was tested (RE-ALIGN trial) and showed increased thrombosis and bleeding.
Choosing Between Agents
- Renal impairment -- Apixaban has the lowest renal dependence and is preferred in CKD. Avoid dabigatran with CrCl <30 mL/min.
- GI bleeding risk -- Apixaban has the lowest GI bleeding rate among DOACs. Dabigatran and rivaroxaban are associated with higher GI bleeding.
- Cost and adherence -- DOACs are more expensive. Twice-daily dosing (dabigatran, apixaban) vs once-daily (rivaroxaban, edoxaban) affects adherence.
Key Takeaways
- DOACs have replaced warfarin as first-line for non-valvular AF and VTE in most patients.
- Warfarin remains essential for mechanical heart valves and antiphospholipid syndrome.
- Renal function must be assessed before and during DOAC therapy.
- Specific reversal agents exist: idarucizumab for dabigatran, andexanet alfa for factor Xa inhibitors.